Anacor Pharmaceuticals' ($ANAC) topical treatment for eczema easily beat placebo in two Phase III trials, sending the biotech's share soaring and setting the stage for FDA application in the first of half of 2016. More from FierceBiotech
Anacor Pharmaceuticals' ($ANAC) topical treatment for eczema easily beat placebo in two Phase III trials, sending the biotech's share soaring and setting the stage for FDA application in the first of half of 2016. More from FierceBiotech